IL246987B - Herteroaryl amides, compositions comprising same and uses thereof - Google Patents

Herteroaryl amides, compositions comprising same and uses thereof

Info

Publication number
IL246987B
IL246987B IL246987A IL24698716A IL246987B IL 246987 B IL246987 B IL 246987B IL 246987 A IL246987 A IL 246987A IL 24698716 A IL24698716 A IL 24698716A IL 246987 B IL246987 B IL 246987B
Authority
IL
Israel
Prior art keywords
preparations containing
heteroaryl amides
heteroaryl
amides
preparations
Prior art date
Application number
IL246987A
Other languages
English (en)
Hebrew (he)
Other versions
IL246987A0 (en
Original Assignee
Neuropore Therapies Inc
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52484559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL246987(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuropore Therapies Inc, UCB Biopharma SRL filed Critical Neuropore Therapies Inc
Publication of IL246987A0 publication Critical patent/IL246987A0/en
Publication of IL246987B publication Critical patent/IL246987B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL246987A 2014-01-29 2016-07-27 Herteroaryl amides, compositions comprising same and uses thereof IL246987B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461933246P 2014-01-29 2014-01-29
US201462078895P 2014-11-12 2014-11-12
PCT/US2015/013263 WO2015116663A1 (en) 2014-01-29 2015-01-28 Heteroarly amides as inhibitors of protein aggregation

Publications (2)

Publication Number Publication Date
IL246987A0 IL246987A0 (en) 2016-09-29
IL246987B true IL246987B (en) 2021-12-01

Family

ID=52484559

Family Applications (1)

Application Number Title Priority Date Filing Date
IL246987A IL246987B (en) 2014-01-29 2016-07-27 Herteroaryl amides, compositions comprising same and uses thereof

Country Status (38)

Country Link
US (3) US9738635B2 (cg-RX-API-DMAC7.html)
EP (2) EP3348556B1 (cg-RX-API-DMAC7.html)
JP (2) JP6619741B2 (cg-RX-API-DMAC7.html)
KR (1) KR102383038B1 (cg-RX-API-DMAC7.html)
CN (2) CN106132960B (cg-RX-API-DMAC7.html)
AP (1) AP2016009347A0 (cg-RX-API-DMAC7.html)
AU (1) AU2015211119B2 (cg-RX-API-DMAC7.html)
BR (2) BR112016017344B1 (cg-RX-API-DMAC7.html)
CA (1) CA2937967C (cg-RX-API-DMAC7.html)
CL (1) CL2016001918A1 (cg-RX-API-DMAC7.html)
CR (1) CR20160394A (cg-RX-API-DMAC7.html)
CY (2) CY1120348T1 (cg-RX-API-DMAC7.html)
DK (2) DK3099684T3 (cg-RX-API-DMAC7.html)
EA (1) EA032374B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP16070327A (cg-RX-API-DMAC7.html)
ES (2) ES2808978T3 (cg-RX-API-DMAC7.html)
HK (1) HK1231470A1 (cg-RX-API-DMAC7.html)
HR (2) HRP20180813T1 (cg-RX-API-DMAC7.html)
HU (2) HUE050964T2 (cg-RX-API-DMAC7.html)
IL (1) IL246987B (cg-RX-API-DMAC7.html)
LT (2) LT3099684T (cg-RX-API-DMAC7.html)
ME (1) ME03800B (cg-RX-API-DMAC7.html)
MX (1) MX2016009896A (cg-RX-API-DMAC7.html)
MY (1) MY187450A (cg-RX-API-DMAC7.html)
NZ (1) NZ722487A (cg-RX-API-DMAC7.html)
PE (1) PE20161393A1 (cg-RX-API-DMAC7.html)
PH (1) PH12016501493A1 (cg-RX-API-DMAC7.html)
PL (2) PL3099684T3 (cg-RX-API-DMAC7.html)
PT (2) PT3099684T (cg-RX-API-DMAC7.html)
RS (2) RS60547B1 (cg-RX-API-DMAC7.html)
SA (1) SA516371579B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201606108RA (cg-RX-API-DMAC7.html)
SI (2) SI3348556T1 (cg-RX-API-DMAC7.html)
SM (2) SMT201800318T1 (cg-RX-API-DMAC7.html)
TR (1) TR201809440T4 (cg-RX-API-DMAC7.html)
UA (1) UA118209C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015116663A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201605246B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE050964T2 (hu) 2014-01-29 2021-01-28 UCB Biopharma SRL Heteroaril amidok mint protein aggregáció inhibitorai
US10975066B2 (en) 2015-07-29 2021-04-13 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
CN106474121B (zh) * 2016-11-25 2017-10-10 刘淑兰 一种治疗慢性盆腔炎的药物
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
WO2018138088A1 (en) * 2017-01-26 2018-08-02 Ucb Biopharma Sprl Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation
RU2019126170A (ru) * 2017-01-26 2021-02-26 Юсб Байофарма Спрл Бисгетероарильные производные в качестве модуляторов агрегации белков
BR112019011931A2 (pt) * 2017-01-26 2019-10-29 Ucb Biopharma Sprl derivados de alcóxi bis-heteroarila como moduladores da agregação de proteína
CA3062749A1 (en) * 2017-05-12 2018-11-15 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Compounds for use in the treatment or prevention of melanoma
CA3108484A1 (en) 2017-08-04 2019-02-07 Anthony Stewart Campbell Inhibitors of microbially induced amyloid
US20200254068A1 (en) * 2017-10-31 2020-08-13 Loma Linda University Methods for treating traumatic brain injury
EP3841100A1 (en) 2018-08-20 2021-06-30 Arvinas Operations, Inc. Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
US20250074902A1 (en) * 2021-12-27 2025-03-06 Shanghai Jingxin Biomedical Co., Ltd. Fused bicyclic heteroaryl amide compound as protein aggregation inhibitor
GB202213796D0 (en) * 2022-09-21 2022-11-02 Wista Lab Ltd Tau aggregation inhibitors
EP4611895A1 (en) * 2022-11-02 2025-09-10 AC Immune SA Novel compounds for the diagnosis of tdp-43 proteinopathies
WO2024184180A1 (en) 2023-03-06 2024-09-12 UCB Biopharma SRL Minzasolmin for use in the treatment of parkinson's disease
WO2024184179A1 (en) 2023-03-06 2024-09-12 UCB Biopharma SRL Minzasolmin for use in the treatment of parkinson's disease
WO2025002040A1 (zh) * 2023-06-25 2025-01-02 上海京新生物医药有限公司 双环杂芳基酰胺化合物的晶型及盐、制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010142801A1 (en) * 2009-06-11 2010-12-16 Katholieke Universiteit Leuven, K.U. Leuven R&D Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1463997A (en) * 1995-12-22 1997-07-17 Acea Pharmaceuticals, Inc. Subtype-selective nmda receptor ligands and the use thereof
RS20050363A (sr) * 2002-11-28 2007-11-15 Schering Aktiengesellschaft, Chk-,Pdk- I Akt-INHIBITORNI PIRIMIDINI, NJIHOVA PROIZVODNJA I UPOTREBA KAO FARMACEUTSKIH SREDSTAVA
CN100536837C (zh) * 2003-02-27 2009-09-09 乔安妮·麦克劳林 鲨肌醇在制备诊断试剂中的用途
TW200530246A (en) * 2003-12-19 2005-09-16 Bristol Myers Squibb Co Azabicyclic heterocycles as cannabinoid receptor modulators
AU2004309368A1 (en) * 2003-12-19 2005-07-14 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
KR20070018824A (ko) * 2003-12-19 2007-02-14 브리스톨-마이어스 스큅 컴퍼니 카나비노이드 수용체 조절제인 아자비사이클릭헤테로사이클
KR100859891B1 (ko) * 2004-08-26 2008-09-23 화이자 인코포레이티드 단백질 키나제 억제제로서 거울상이성질체적으로 순수한아미노헤테로아릴 화합물
EP1797084A1 (en) * 2004-09-20 2007-06-20 4Sc Ag NOVEL HETEROCYCLIC NF-kB INHIBITORS
SE0403119D0 (sv) * 2004-12-21 2004-12-21 Astrazeneca Ab Therapeutic agents
JP2009505948A (ja) * 2005-07-11 2009-02-12 デブジェン エヌブイ キナーゼ阻害剤としてのアミド誘導体
WO2007016979A2 (en) * 2005-07-29 2007-02-15 4Sc Ag NOVEL HETEROCYCLIC NF-κB INHIBITORS
BRPI0709595A2 (pt) * 2006-03-15 2011-07-19 4Sc Ag inibidores de nf-kapab heterocìclicos
EP2081892A4 (en) * 2006-11-17 2014-03-05 Donald F Weaver COMPOUNDS AND METHOD FOR THE TREATMENT OF PROTEIN DISAPPEARANCE
EP2155226A4 (en) * 2007-06-14 2010-07-28 Univ California COMPOUNDS FOR INHIBITING THE PROTEIN AGGREGATION AND METHOD FOR THE PRODUCTION AND USE THEREOF
WO2010068452A1 (en) * 2008-11-25 2010-06-17 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
WO2011048525A1 (en) * 2009-10-20 2011-04-28 Pfizer Inc. Novel heteroaryl imidazoles and heteroaryl triazoles as gamma-secretase modulators
NZ600449A (en) * 2009-12-16 2014-10-31 Neuropore Therapies Inc Compound suitable for the treatment of synucleopathies
GB201021103D0 (en) * 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
WO2013134371A1 (en) 2012-03-06 2013-09-12 Neuropore Therapies, Inc. Methods and compounds to be used in the treatment of neurodegenerative diseases
RU2014143242A (ru) 2012-03-28 2016-05-20 Ньюропор Терапис, Инк. Производные фенилмочевины и фенилкарбаматов в качестве ингибиторов агрегации белка
CN104703604A (zh) * 2012-07-16 2015-06-10 神经孔疗法股份有限公司 作为蛋白质聚集抑制剂的二-和三-杂芳基衍生物
HUE050964T2 (hu) 2014-01-29 2021-01-28 UCB Biopharma SRL Heteroaril amidok mint protein aggregáció inhibitorai
US10975066B2 (en) 2015-07-29 2021-04-13 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
RU2019126170A (ru) 2017-01-26 2021-02-26 Юсб Байофарма Спрл Бисгетероарильные производные в качестве модуляторов агрегации белков
WO2018138088A1 (en) 2017-01-26 2018-08-02 Ucb Biopharma Sprl Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010142801A1 (en) * 2009-06-11 2010-12-16 Katholieke Universiteit Leuven, K.U. Leuven R&D Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
AU2015211119B2 (en) 2019-05-30
EP3099684A1 (en) 2016-12-07
PL3099684T3 (pl) 2018-09-28
DK3348556T3 (da) 2020-08-03
BR112016017344A2 (pt) 2017-10-03
HK1231470A1 (zh) 2017-12-22
US20180093979A1 (en) 2018-04-05
CN106132960B (zh) 2019-12-17
HRP20201107T8 (hr) 2020-12-11
EP3348556B1 (en) 2020-04-29
TR201809440T4 (tr) 2018-07-23
EP3099684B8 (en) 2018-07-04
ECSP16070327A (es) 2018-05-31
JP2017505779A (ja) 2017-02-23
EP3099684B1 (en) 2018-04-04
WO2015116663A8 (en) 2016-09-15
LT3099684T (lt) 2018-06-25
HRP20201107T1 (hr) 2020-10-30
SI3348556T1 (sl) 2020-10-30
MX2016009896A (es) 2017-01-11
BR122018001892B1 (pt) 2023-05-02
EA032374B1 (ru) 2019-05-31
AU2015211119A1 (en) 2016-08-11
SMT202000376T1 (it) 2020-09-10
CL2016001918A1 (es) 2017-01-13
US10358443B2 (en) 2019-07-23
US9738635B2 (en) 2017-08-22
KR20160113287A (ko) 2016-09-28
SI3099684T1 (en) 2018-08-31
US11078196B2 (en) 2021-08-03
ES2808978T8 (es) 2021-03-22
EP3348556A1 (en) 2018-07-18
RS60547B1 (sr) 2020-08-31
MY187450A (en) 2021-09-22
ES2675301T3 (es) 2018-07-10
CN111039939B (zh) 2023-09-19
IL246987A0 (en) 2016-09-29
NZ722487A (en) 2022-04-29
US20190308965A1 (en) 2019-10-10
PH12016501493B1 (en) 2017-02-06
UA118209C2 (uk) 2018-12-10
WO2015116663A1 (en) 2015-08-06
DK3099684T3 (en) 2018-07-16
SG11201606108RA (en) 2016-08-30
PT3348556T (pt) 2020-07-27
CA2937967A1 (en) 2015-08-06
CN111039939A (zh) 2020-04-21
LT3348556T (lt) 2020-08-10
RS57533B1 (sr) 2018-10-31
CN106132960A (zh) 2016-11-16
ZA201605246B (en) 2022-05-25
US20160207912A1 (en) 2016-07-21
PL3348556T3 (pl) 2020-11-02
HUE040274T2 (hu) 2019-03-28
EA201691529A1 (ru) 2017-01-30
ME03800B (me) 2021-04-20
HUE050964T2 (hu) 2021-01-28
KR102383038B1 (ko) 2022-04-05
ES2808978T3 (es) 2021-03-02
AP2016009347A0 (en) 2016-07-31
CY1120348T1 (el) 2019-07-10
JP6619741B2 (ja) 2019-12-11
CR20160394A (es) 2016-11-01
CA2937967C (en) 2022-07-26
JP6783900B2 (ja) 2020-11-11
BR112016017344B1 (pt) 2023-05-16
SA516371579B1 (ar) 2019-07-16
PH12016501493A1 (en) 2017-02-06
AU2015211119A8 (en) 2016-12-15
PT3099684T (pt) 2018-10-22
HRP20180813T1 (hr) 2018-07-27
PE20161393A1 (es) 2017-01-08
CY1123374T1 (el) 2021-12-31
JP2019163321A (ja) 2019-09-26
SMT201800318T1 (it) 2018-07-17

Similar Documents

Publication Publication Date Title
IL304772A (en) Antibodies, uses and methods
IL272089A (en) Compounds, compositions and methods
IL246987B (en) Herteroaryl amides, compositions comprising same and uses thereof
IL256260B (en) Treprostinil derivatives and compositions and uses thereof
IL248740A0 (en) Compositions for mosquito control and uses of same
IL264454A (en) Novel compositions, uses and methods for making them
HRP20180501T1 (hr) Pripravci koje sadrže bakterijske sojeve
HRP20180810T1 (hr) Pripravci koji sadrže bakterijske sojeve
HRP20182170T1 (hr) Pripravci koji sadrže bakterijske sojeve
IL240196A0 (en) Amide compounds, compositions comprising same and uses thereof
HUE053737T2 (hu) Piridopirrolokinoxalin vegyületek, készítményeik és alkalmazásaik
IL252346B (en) Heteroaryl compounds, their preparation and use
IL249639A0 (en) Endophytes, associated compositions, and methods of use thereof
IL240195A0 (en) Pyridone amide compounds, compositions comprising same and uses thereof
IL247262A0 (en) Cannabinoid compositions and uses
DK3149042T3 (da) PD-L1-antistoffer og anvendelser deraf
DK3229838T3 (da) Anti-C10orf54-antistoffer og anvendelser deraf
DK3126388T3 (da) Anti-EGFRvIII-antistoffer og anvendelser deraf
EP3205103C0 (en) INTER AND INTRA UNIFICATION BLOCK COPY
HUE054344T2 (hu) Gyógyászati készítmények AZD9291 tartalommal
IL256939B (en) Rapid-acting insulin compositions
KR102061390B9 (ko) 구아니딘 화합물 및 그의 용도
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
HUE045024T2 (hu) Poliamid készítmények
DK3209773T3 (da) Prolintolerante tripeptidylpeptidaser og anvendelser deraf